← Leaderboards
Stephen C Lam
British Columbia Cancer Agency
$5,084,888
Attributed
$6,656,011
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $845.6K · FY2005–14$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$6,656,011 · 2
By mechanism
U01$4,561,180 · 1
R01$2,094,831 · 1
Top collaborators
- Marc Elliott Lenburg4 shared
- Don Sin4 shared
- Avrum E Spira4 shared
Most similar at British Columbia Cancer Agency
Same institution · by research overlap
- Miriam P. Rosin$3,988,890
- Wan L Lam$1,059,664
Others in their field
Top investigators on “Lung Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$351,628,955
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,374,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,110,512
- William J. Blot · Vanderbilt University$59,429,890
- Charles A Coltman · Southwest Oncology Group$54,703,213
Research focus
Lung NeoplasmsChemopreventionNeoplasm /Cancer DiagnosisAdenocarcinomaBenignAirway EpitheliumAppearanceBostonBritish ColumbiaBronchoscopyCancer CellCancer ChemopreventionCancer DiagnosisCancer PreventionCarcinogenesisCancer RiskCarcinogenesis InhibitorCase-Control StudiesCharacteristicsAlternative MedicineChronic Obstructive Airway DiseaseClinically RelevantClinical ResearchAffect
Grant awards (9)
Molecular biomarkers of airway and lung linking COPD and Lung Cancer$499,578
R01 · FY2014 · CA
Molecular biomarkers of airway and lung linking COPD and Lung Cancer$496,897
R01 · FY2013 · CA
Molecular biomarkers of airway and lung linking COPD and Lung Cancer$535,797
R01 · FY2012 · CA
Molecular biomarkers of airway and lung linking COPD and Lung Cancer$562,559
R01 · FY2011 · CA
A Phase II Trial of ACAPHA in Former Smokers with IEN.$590,472
U01 · FY2006 · CA · contact PI
A Phase II Trial of ACAPHA in Former Smokers with IEN.$845,564
U01 · FY2005 · CA
A Phase II Trial of ACAPHA in Former Smokers with IEN.$989,903
U01 · FY2004 · CA
A Phase II Trial of ACAPHA in Former Smokers with IEN.$1,092,902
U01 · FY2003 · CA
A Phase II Trial of ACAPHA in Former Smokers with IEN.$1,042,339
U01 · FY2002 · CA